Intravenous (IV) Sotrovimab

Indication	Treatment of adults with acute Covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe Covid-19 infection.
Dose	In adults weighing >40kg: 500mg sotrovimab in 108ml sodium chloride 0.9% STAT dose administered as a single IV infusion (as soon as possible) within 5 days of symptoms onset and a positive PCR test.
Preparation	Sotrovimab vials contain 500mg in 8ml. 1. Withdraw 8ml (500mg) sotrovimab from the vial using a 10ml syringe. 2. Add to a 100ml bag of sodium chloride 0.9%. 3. This will produce a total volume of 108ml. 4. Gently rock the bag back and forth 3 to 5 times. Do NOT invert OR shake the bag to help avoid forming air bubbles. 5. Record brand, batch no. & expiry of sotrovimab in patient's bedside folder. 6. Discard any unused sotrovimab left in the vial.
Administration	This medicine must be diluted prior to administration (see notes under 'preparation' above). Administer infusion over 30 minutes during last 30 minutes of dialysis using an infusion pump via a 0.2-µm in-line filter. NB: These should be stocked on the dialysis unit, but if unavailable please contact pharmacy to provide one.
Shelf-life	The sotrovimab vial should be stored in a refrigerator at (2℃ – 8℃) until needed. Once the infusion has been prepared, the product should be used immediately.
Additional information	Once prepared, the infusion solution should be a clear, colourless or yellow to brown solution, free from visible particles. Sotrovimab should not be infused concomitantly in the same intravenous line with other medication. No dose adjustment is recommended in patients with renal impairment or liver impairment or in elderly patients. Please see link below on direction for safe handling of mAb products: https://www.medusaimg.nhs.uk/docs/mAb%20Products%205th%20Edition%202015.pdf
Monitoring	Patients should be monitored during infusion and for 60 minutes after. Monitor for signs of hypersensitivity, anaphylaxis, and infusion-related reactions. If the patient is developing signs of an anaphylactic reaction the medical team must be contacted urgently. The rate of infusion may be slowed, interrupted, or discontinued if the patient develops any signs of infusion-associated events or other adverse events.

Sample Label

DRUGS ADDED TO THIS INFUSION			
PATIENT A. Patient (A. Number)			WARD RDU
DRUG IV sotrovimab *Infuse over 30 minutes during last 30 minutes of dialysis*	AMOUNT 500mg in 108ml NaCl0.9%	ADDED BY	CHECK BY
DATE ADDED TIME ADDED	EXPIRY USE IMMEDIATELY		BATCH No.
DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS			

Written by: Maya Daas (Advanced Pharmacist – Renal Services)
and Azeem Akhtar (Specialist Pharmacist - Renal and Specialist Medicine)
Aug 2024

Checked by: Hester Smail - Divisional Lead Pharmacist - Specialist Medicine

Approved by: Dr Joanna McKinnell - Consultant Renal Physician

For review: Aug 2026

Key contact: Advanced Pharmacist – Renal Services

References:

https://www.renaldrugdatabase.com/s/article/SOTROVIMAB
Last accessed: 20.08.2024

https://www.medicines.org.uk/emc/product/13097
Last accessed: 20.08.2024

https://www.new.medicinescomplete.com/#/content/bnf/_623260169?hspl=Sotrovimab
Last accessed: 20.08.2024

https://www.medusaimg.nhs.uk/docs/mAb%20Products%205th%20Edition%202015.pdf
Last accessed: 20.08.2024